I think you missed the footnote; (which was a little shoddy itself)
*Market cap data for PRAN and AVXL are the historical values from when the companies were mid Phase II and I, respectively."
The point I think they were making is that the MC he listed was before these companies completed their Ph2 trials, both of which have gone significantly lower after not so good results.